Evorpacept - ALX Oncology
Alternative Names: ALX-148; CD47/SIRPa-blocking Agent ALX 148; SIRPa Variant ALX 148Latest Information Update: 06 Jun 2024
At a glance
- Originator Alexo Therapeutics
- Developer ALX Oncology; Eli Lilly and Company; Merck & Co; Merck Sharp & Dohme; Quantum Leap Healthcare Collaborative; University of California; Zymeworks
- Class Antineoplastics; Immunoglobulin Fc fragments; Immunotherapies; Proteins; Recombinant fusion proteins
- Mechanism of Action CD47 antigen inhibitors; Cytotoxic T lymphocyte stimulants; Dendritic cell stimulants; Phagocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Gastric cancer
- Phase II Colorectal cancer; Oropharyngeal cancer; Squamous cell cancer
- Phase I/II Acute myeloid leukaemia; HER2 positive breast cancer; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Solid tumours
- Phase I Breast cancer; Urogenital cancer
- Preclinical Multiple myeloma
Most Recent Events
- 02 Jun 2024 Efficacy and adverse event data from a phase I trial in Urogenital cancer released by ALX Oncology
- 31 May 2024 Efficacy and adverse event data from a phase I trial in Urogenital cancer presented at 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 31 May 2024 Efficacy and adverse events data from a phase II trial in Colorectal cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)